Managing Inflammatory Myofibroblastic Tumor of the Uterus: A Case Report and Comprehensive Review of Pathological and Therapeutic Approaches

Xuechao Ji; Peiling Zhai; Hui Wang; Hanchao Yang; Xinbo Wang

doi:10.12659/AJCR.941519

13 November 2023 : Case report China (mainland)

Managing Inflammatory Myofibroblastic Tumor of the Uterus: A Case Report and Comprehensive Review of Pathological and Therapeutic Approaches

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease

Xuechao Ji^12ABE, Peiling Zhai^1ABE, Hui Wang^1CDF, Hanchao Yang^3CF, Xinbo Wang^1FG*

DOI: 10.12659/AJCR.941519

Am J Case Rep 2023; 24:e941519

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 3. Uterine inflammatory myofibroblastic tumor. (A) Most tumor cells were arranged in fascicles with scattered lymphocyte infiltration. (B) Immunohistochemical staining for SMA was positive. (C) Tumor cells in the myxoid areas were strongly positive for ALK. (Hematoxylin-eosin, [A]; original magnification 200× [A-C]). SMA – smooth-muscle actin; ALK – anaplastic lymphoma kinase.

Back to the Article

Managing Inflammatory Myofibroblastic Tumor of the Uterus: A Case Report and Comprehensive Review of Pathological and Therapeutic Approaches

Your Privacy